Literature DB >> 1394147

In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells.

W H Sun1, R A Kreisle, A W Phillips, W B Ershler.   

Abstract

Interleukin 6 (IL-6) is a multifunctional cytokine important in the inflammatory response. Its potential role as an antitumor agent has been suggested by its demonstrated activity in a variety of tumor models. The mechanism of antitumor activity has been proposed to be its enhancement of cytotoxic T-cell function. In the current work we demonstrate clear antitumor activity for this cytokine in a nonimmunogenic tumor system. B16 melanoma cells transfected with the human IL-6 complementary DNA demonstrated slower tumor growth in vivo. Tumors that developed from these cells had a prominent stromal matrix, an easily recognized infiltration of inflammatory cells, fewer mitotic figures, and fewer blood vessels. These in vivo findings corresponded with a greater adhesion of the IL-6-transfected B16 cells to stromal matrix proteins (laminin, fibronectin, and vitronectin) and a less prominent vascular response in an intradermal angiogenesis assay. Therefore, we propose that with weakly antigenic tumors, such as B16 melanoma, IL-6 may mediate important antitumor responses by nonspecific proinflammatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394147

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant.

Authors:  T Ohira; Y Ohe; Y Heike; E R Podack; K J Olsen; K Nishio; M Nishio; Y Miyahara; Y Funayama; H Ogasawara
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  In vivo cytokine gene transfer by gene gun reduces tumor growth in mice.

Authors:  W H Sun; J K Burkholder; J Sun; J Culp; J Turner; X G Lu; T D Pugh; W B Ershler; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

3.  Preliminary study on the cooperation of IL-6 and mB7-1 in the induction of effective antitumor immunity in vitro.

Authors:  S Qu; R Liu; Y Wang; J Wang
Journal:  J Tongji Med Univ       Date:  1999

4.  Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors.

Authors:  M P Colombo; L Lombardi; C Melani; M Parenza; C Baroni; L Ruco; A Stoppacciaro
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

Review 5.  The role of interleukin-6 in certain age-related diseases.

Authors:  W B Ershler; W H Sun; N Binkley
Journal:  Drugs Aging       Date:  1994-11       Impact factor: 3.923

Review 6.  Breast cancer gene therapy: transgenic immunotherapy.

Authors:  N Su; J O Ojeifo; A MacPherson; J A Zwiebel
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.

Authors:  X Cao; W Zhang; S Gu; Y Yu; Q Tao; T Ye
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta.

Authors:  Miyako Okamoto; Weimin Liu; Yuchun Luo; Aki Tanaka; Xiangna Cai; David A Norris; Charles A Dinarello; Mayumi Fujita
Journal:  J Biol Chem       Date:  2009-12-28       Impact factor: 5.157

9.  A model for cancer-suppressive inflammation.

Authors:  Ole Audun Werner Haabeth; Bjarne Bogen; Alexandre Corthay
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

10.  Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.

Authors:  A Stoppacciaro; C Melani; M Parenza; A Mastracchio; C Bassi; C Baroni; G Parmiani; M P Colombo
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.